| Literature DB >> 25502297 |
Abstract
Substance use disorders (SUDs) are highly prevalent. SUDs involve vicious cycles of binges followed by occasional periods of abstinence with recurrent relapses despite treatment and adverse medical and psychosocial consequences. There is convincing evidence that early and adult stressful life events are risks factors for the development of addiction and serve as cues that trigger relapses. Nevertheless, the fact that not all individuals who face traumatic events develop addiction to licit or illicit drugs suggests the existence of individual and/or familial resilient factors that protect these mentally healthy individuals. Here, I give a brief overview of the epigenetic bases of responses to stressful events and of epigenetic changes associated with the administration of drugs of abuse. I also discuss the psychobiology of resilience and alterations in epigenetic markers that have been observed in models of resilience. Finally, I suggest the possibility that treatment of addiction should involve cognitive and pharmacological approaches that enhance resilience in at risk individuals. Similar approaches should also be used with patients who have already succumbed to the nefarious effects of addictive substances.Entities:
Keywords: Alcohol; Cocaine; DNA methylation; Heroin; Histone acetylation; Methamphetamine; Nicotine
Mesh:
Year: 2014 PMID: 25502297 PMCID: PMC4703633 DOI: 10.1007/s12035-014-9040-y
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.590
Fig. 1Schema showing the potential interactions of drugs of abuse with an individual’s genome and the impact of environmental vicissitudes on the individual’s responses to these agents. The epigenetic responses to the drug will probably be dependent on the genetic background, family resilient factors, and environmental stressors that individuals face during their lifetimes. Substance use disorders (addiction) are thus viewed not as reductionist constructs but as multifactorial complex neuropsychiatric disorders, with only a few individuals actually developing those syndromes after trying various rewarding substances. This statement suggests the need to develop more animal models that take these issues into consideration. By extension, our pharmacological treatments may thus be bound to fail because present approaches of developing therapeutic agents employ all animals that self-administer a drug in question whereas only a few percentages of humans become addicted to a licit or illicit substance. The schema also suggests the need to identify resilient factors within individuals and families that treatment personnel can shore up within addicted individuals and teach to those who are living in high-risk situations